key: cord-0810974-gg0419c8 authors: Romano, Sónia; Galante, Heloísa; Figueira, Débora; Mendes, Zilda; Rodrigues, António Teixeira title: Time-trend analysis of medicine sales and shortages during COVID-19 outbreak: Data from community pharmacies date: 2020-05-23 journal: Res Social Adm Pharm DOI: 10.1016/j.sapharm.2020.05.024 sha: 58b1f0c4f27ad2ff06700a14cc2adafe6ae94c48 doc_id: 810974 cord_uid: gg0419c8 BACKGROUND: COVID-19 is a worldwide public health concern. Disruptions in the drug market are expected and shortages might worsen. Community pharmacies can contribute to early identification and report of medicines’ supply and demand issues. OBJECTIVE: The aim of this study is to characterize the impact of the COVID-19 outbreak on outpatient medicines’ sales and shortages. METHODS: A retrospective, time-trend analysis of medicine sales, shortages and laboratory-confirmed COVID-19 cases was performed from February 1st to April 30th, 2020, and its homologous period (regarding sales only). A detailed analysis of 6 pharmaceutical substances was performed. All data were subjected to rescaling using the min-max normalization method, in order to become comparable. Data analysis was performed using Microsoft® Excel. RESULTS: The pandemic resulted in an increase in medicines’ demand and reported shortages during the early stage of the outbreak. The maximum proportion of medicine sales was registered on March 13th, 2020, 4 days after the WHO declared COVID-19 a pandemic. By the end of March, sales have already dropped to proportions similar to those of 2019. The maximum proportion of drug shortages was reached about one week after the sales peak and by the end of the study period were below those recorded in the pre-COVID-19 period. The analyzed drugs were paracetamol, ascorbic acid, dapagliflozin plus metformin, rosuvastatin plus ezetimibe, formoterol, and hydroxychloroquine, as these pharmaceutical substances registered the highest growth rate in sales and shortages when compared to the same period in the previous year. Hydroxychloroquine showed the most different pattern trends on sales and shortages of these medicines. CONCLUSIONS: Pharmacies can provide timely and real-world data regarding sales and shortages. The adopted measures to guarantee the continuous supply of the medicine market seem to have worked. The long-term impacts of this pandemic are unknown and should continue to be closely monitored. On January 30 th 2020, the World Health Organization (WHO) designated the COVID-19 30 outbreak a public health emergency of international concern and on March 11 th it was 31 declared a global pandemic. 1 By May 19 th , 216 countries, areas or territories worldwide had 32 reported almost 5 million cases of coronavirus disease. 2 Preventive measures to flatten the 33 epidemic curve have been implemented, thereby avoiding a demand surge on the healthcare 34 system. Alongside the need to guarantee the supply of key medical and personal protective 35 equipment to control the disease, there is a general concern regarding the preservation of the 36 continued supply of medicines for all citizens. [3] [4] [5] Although no major disruptions in 37 pharmaceutical access have been reported thus far, the existing issue of medicine shortages 6-9 38 may increase, due to the worldwide state of public health emergency. Expected constraints in 39 the manufacturing process (e.g. lockdown of factories due to quarantine) and supply chain 40 disruptions can affect countries' ability to ensure patients' access to pharmacological 41 therapies. Moreover, people's behavior is known to change during an epidemic 10 . Its 42 constraints can lead to states of anxiety, hoarding of medical supplies and rioting. 11 As a result, 43 an increase in the demand for medicines is anticipated, which may enhance the issue of drug 44 shortages, acknowledged for having a negative impact on population welfare, leading to higher 45 demand in healthcare resources and increased morbidity and mortality. 12 46 Community pharmacies play an important public health role by ensuring the continuous and 47 rational supply of medicines, contributing to patients' education, managing stockpiling and 48 early identification and report of unavailable medicines. 13, 14 This study aims to characterize the 49 impact of the COVID-19 outbreak on the outpatient medicines' sales and shortages. 50 51 Methods 52 A retrospective, time-trend analysis of total medicine sales, shortages and new laboratory-53 confirmed COVID-19 cases was performed from February 1 st to April 30 th , 2020 and its 54 homologous period (regarding sales only). To get a better insight of the market trends' 55 specificities, a detailed analysis of 6 pharmaceutical substances was performed. The selection 56 took in consideration the substances from different therapeutic classes with the highest 57 growth rates simultaneously in sales and shortages, when compared to the homologous 58 period. These substances were identified by International Non-proprietary Name (INN) and 59 Anatomical Therapeutic Chemical (ATC/WHO) classification code. Medicine sales were retrieved from a national representative panel of community pharmacies 62 with Sifarma®-dispensing software (n≈2400, 83% of the total number of Portuguese 63 pharmacies). Data are collected daily and stored in a data warehouse since 2002. 64 In this study, the term 'medicine shortages' is used to describe the pharmacy medicine orders 66 that were unfulfilled by the wholesale distributors. All pharmacies with Sifarma® have an 67 application installed that allows them to, voluntarily and daily, report the ordered prescription-68 only-medicines (POMs) and over-the-counter (OTC) pharmaceutical products that were not 69 delivered to the pharmacy. week, total sales dropped into a normal range. The maximum value of new daily COVID-19 150 cases was registered on April 10 th . This peak was reached not only because of new infections 151 but also due to an increase in the number of analyzed samples during that week. 13 In light of the initial increased demand for medicines and to prevent stockpiling, national 153 authorities have taken several emergency responses. 4 For example, it has been recommended 154 that users should only buy one package of OTCs, with special emphasis for paracetamol 155 presentations. As for POMs, guidelines and later legislation imposed restrictions on the 156 quantities that can be purchased by citizens. Pharmacies can no longer fully dispense 6-month 157 renewal prescriptions at once. The maximum amount allowed to avoid inequities and ensure 158 that all patients receive the medicines they need is the number of packages required for 159 treatment for up to two months. 19 Also, in line with recent EU guidelines 20 , pharmacies were 160 permitted to deliver POMs to peoples' homes. This measure intended to prevent patients from 161 hoarding medicines, going to the pharmacy as frequently and be exposed to the coronavirus. 21 162 In order to aid pharmacies in providing this service to the population, the Portuguese National 163 Association of Pharmacies, which represents about 94% of community pharmacies, 164 established a partnership with the Portuguese Post Office. These immediate measures 165 seem to be successful in helping to control high demand, as up to date sales have dropped 166 below pre-outbreak levels (Figure 1) . 167 As for drug shortages, and despite the registered increment in the two weeks following the 168 sales peak, their proportions dropped to lower values than those reported before the outbreak 169 Some limitations to this paper should be noted. When it comes to data collection, as monthly 235 medicine sales are validated in the second half of the following month, the presented values 236 for April are provisional estimates. However, the amount of sales removed by the validation 237 process is extremely low, which allows the use of these estimates for analyses without the risk 238 of major differences in data. Unfulfilled pharmacy orders were used as a proxy of medicine 239 shortages, thus do not represent a direct report from patients, but can be used to study trends 240 as all pharmacies report them the same way. Also, since medicine shortages are dependent on 241 the pharmacists' direct report, it is important to consider that, in this period, pharmacies are 242 working under very controlled conditions (e.g. reduced teams) and therefore may not report 243 all their unfulfilled orders, i.e., this registry may suffer from underreporting. Regarding data 244 analysis, namely the analysis of the INNs, it was assumed that the medicine sales and 245 shortages registered on the first week of March were representative of the pre-COVID-19 246 period values, as this can be observed for the total medications' market ( Figure 2) . 247 248 Pharmacies are able to provide timely and real-world outpatient market data to monitor 250 medicines' trends, which in turn can help national and European regulatory and policy entities 251 take coordinated actions and propose guidelines regarding preventive management of 252 medicines in response to public health crisis, such as COVID-19. Data suggest that medicines' 253 sales and shortages were impacted by the COVID-19 lockdown in Portugal, although measures 254 taken seem to have led to the stabilization of the market. The long-term impacts of this 255 pandemic are unknown and should continue to be closely monitored. 256 257 The authors declare that they have no known competing personal or financial interests that 259 could influence this research. We want to gratefully acknowledge all community pharmacies who voluntarily agreed to share 272 their sell-out and unfulfilled wholesale orders' data. 273 The data that support the findings of this study are available from the corresponding author on 276 reasonable request. 277 278 Director-General's opening remarks at the media briefing on INFARMED (National Authority of Medicines and Health Products Orientações Para a Gestão Responsável de 288 Medicamentos No Actual Contexto de Pandemia COVID-19 (in Portuguese) INFARMED (National Authority of Medicines and Health Products, I.P.) and DGS 291 (General Directorate of Health). NORMA 003/2020. Infeção Por SARS-Cov-2 (COVID-19) 292 (in Portuguese) Addressing the potential impact of novel 294 coronavirus disease (COVID-19) on medicines supply in the EU Drug Shortages: Patients and 298 Health Care Providers Are All Drawing the Short Straw Economic and Policy Implications 301 of Drug Shortages in the European Union. Appl Health Econ Health Policy Drug Shortages: A Complex Health Care Crisis Drug shortages may 307 compromise patient safety: Results of a survey of the reference pharmacies of the Drug 308 Commission of German Pharmacists. Health Policy (New York) Pandemic: Information and Interim Guidelines for Pharmacists and the Pharmacy 320 INFARMED (National Authority of Medicines and Health Products Ponto de Situação Atual em Portugal -COVID-19 325 Normalization: A Preprocessing Stage Ordinance No 90-A/2020 of April 9 Prescrição Eletrónica de Medicamentos e Respetiva Receita Médica European Commission. Communication from the Commission. Guidelines on the 338 Optimal and Rational INFARMED (National Authority of Medicines and Health Products, I.P.) Informativa 066/CD/100.2.200 Atualização Da Lista de Medicamentos Abrangidos Pela 345 Notificação Prévia de Exportação Ou Distribuição Para Outros Estados Membros Europe faces worsening medicine shortages INFARMED (National Authority of Medicines and Health Products, I.P.) Estimation During the COVID-19 Pandemic: Preliminary Data from Portugal DGS (General Directorate of Health). Mortality Surveillance Review of the Clinical Characteristics 359 of Coronavirus Disease 2019 (COVID-19) Effect of Vitamin C Infusion on Organ Failure and 364 Biomarkers of Inflammation and Vascular Injury in Patients with Sepsis and Severe European Medicines Agency (EMA). Update on treatments and vaccines against COVID-368 19 under development An update of its pharmacological properties and 372 therapeutic efficacy in the management of asthma Combination Therapy of Rosuvastatin and Ezetimibe in 375 Patients with High Cardiovascular Risk Combination therapy for type 2 diabetes: Dapagliflozin plus metformin New regulatory strategies to manage medicines 380 shortages in Europe Hydroxychloroquine and azithromycin as a 383 treatment of COVID-19: results of an open-label non-randomized clinical trial Breakthrough: Chloroquine phosphate has shown apparent 386 efficacy in treatment of COVID-19 associated pneumonia in clinical studies COVID-19: chloroquine and hydroxychloroquine 392 only to be used in clinical trials or emergency use programmes 394 be-used-clinical-trials-emergency-use-programmes. Accessed National Institute of Diabetes and Digestive and Kidney Diseases